These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26267065)

  • 1. The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy.
    Jørgenrud B; Jalanko M; Heliö T; Jääskeläinen P; Laine M; Hilvo M; Nieminen MS; Laakso M; Hyötyläinen T; Orešič M; Kuusisto J
    PLoS One; 2015; 10(8):e0134184. PubMed ID: 26267065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMR derived left ventricular septal convexity in carriers of the hypertrophic cardiomyopathy-causing MYBPC3-Q1061X mutation.
    Tarkiainen M; Sipola P; Jalanko M; Heliö T; Jääskeläinen P; Kivelä K; Laine M; Lauerma K; Kuusisto J
    Sci Rep; 2019 Apr; 9(1):5960. PubMed ID: 30976029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular magnetic resonance of mitral valve length in hypertrophic cardiomyopathy.
    Tarkiainen M; Sipola P; Jalanko M; Heliö T; Laine M; Järvinen V; Häyrinen K; Lauerma K; Kuusisto J
    J Cardiovasc Magn Reson; 2016 Jun; 18(1):33. PubMed ID: 27259862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes.
    Poutanen T; Tikanoja T; Jääskeläinen P; Jokinen E; Silvast A; Laakso M; Kuusisto J
    Am Heart J; 2006 Mar; 151(3):725.e1-725.e9. PubMed ID: 16504640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population.
    Jääskeläinen P; Heliö T; Aalto-Setälä K; Kaartinen M; Ilveskoski E; Hämäläinen L; Melin J; Nieminen MS; Laakso M; Kuusisto J; ; Kervinen H; Mustonen J; Juvonen J; Niemi M; Uusimaa P; Huttunen M; Kotila M; Pietilä M
    Ann Med; 2013 Feb; 45(1):85-90. PubMed ID: 22462493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertrophic cardiomyopathy in myosin-binding protein C (
    Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
    Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new common mutation in the cardiac beta-myosin heavy chain gene in Finnish patients with hypertrophic cardiomyopathy.
    Jääskeläinen P; Heliö T; Aalto-Setälä K; Kaartinen M; Ilveskoski E; Hämäläinen L; Melin J; Kärkkäinen S; Peuhkurinen K; Nieminen MS; Laakso M; ; Kuusisto J
    Ann Med; 2014 Sep; 46(6):424-9. PubMed ID: 24888384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.
    Michels M; Soliman OI; Kofflard MJ; Hoedemaekers YM; Dooijes D; Majoor-Krakauer D; ten Cate FJ
    JACC Cardiovasc Imaging; 2009 Jan; 2(1):58-64. PubMed ID: 19356534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel cardiac myosin-binding protein C S297X mutation in hypertrophic cardiomyopathy.
    Hirota T; Kubo T; Kitaoka H; Hamada T; Baba Y; Hayato K; Okawa M; Yamasaki N; Matsumura Y; Yabe T; Doi YL
    J Cardiol; 2010 Jul; 56(1):59-65. PubMed ID: 20350521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Echocardiographic Strain Abnormalities Precede Left Ventricular Hypertrophy Development in Hypertrophic Cardiomyopathy Mutation Carriers.
    Canciello G; Lombardi R; Borrelli F; Ordine L; Chen SN; Santoro C; Frisso G; di Napoli S; Polizzi R; Cristiano S; Esposito G; Losi MA
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.
    van Velzen HG; Schinkel AFL; Oldenburg RA; van Slegtenhorst MA; Frohn-Mulder IME; van der Velden J; Michels M
    Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28794111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
    Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
    PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland.
    Jääskeläinen P; Kuusisto J; Miettinen R; Kärkkäinen P; Kärkkäinen S; Heikkinen S; Peltola P; Pihlajamäki J; Vauhkonen I; Laakso M
    J Mol Med (Berl); 2002 Jul; 80(7):412-22. PubMed ID: 12110947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
    Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
    J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mutation in the cardiac myosin-binding protein C gene is responsible for hypertrophic cardiomyopathy with severe ventricular hypertrophy and sudden death.
    Konno T; Shimizu M; Ino H; Fujino N; Uchiyama K; Mabuchi T; Sakata K; Kaneda T; Fujita T; Masuta E; Mabuchi H
    Clin Sci (Lond); 2006 Jan; 110(1):125-31. PubMed ID: 16181148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.
    Fraysse B; Weinberger F; Bardswell SC; Cuello F; Vignier N; Geertz B; Starbatty J; Krämer E; Coirault C; Eschenhagen T; Kentish JC; Avkiran M; Carrier L
    J Mol Cell Cardiol; 2012 Jun; 52(6):1299-307. PubMed ID: 22465693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.
    Schlossarek S; Schuermann F; Geertz B; Mearini G; Eschenhagen T; Carrier L
    J Muscle Res Cell Motil; 2012 May; 33(1):5-15. PubMed ID: 22076249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction.
    Timmer SA; Germans T; Brouwer WP; Lubberink M; van der Velden J; Wilde AA; Christiaans I; Lammertsma AA; Knaapen P; van Rossum AC
    Eur J Heart Fail; 2011 Dec; 13(12):1283-9. PubMed ID: 22021246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel electrocardiographic features in carriers of hypertrophic cardiomyopathy causing sarcomeric mutations.
    Jalanko M; Heliö T; Mustonen P; Kokkonen J; Huhtala H; Laine M; Jääskeläinen P; Tarkiainen M; Lauerma K; Sipola P; Laakso M; Kuusisto J; Nikus K
    J Electrocardiol; 2018; 51(6):983-989. PubMed ID: 30497761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
    Van Driest SL; Vasile VC; Ommen SR; Will ML; Tajik AJ; Gersh BJ; Ackerman MJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1903-10. PubMed ID: 15519027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.